These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38349444)

  • 1. Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes.
    Ntostoglou K; Theodorou SDP; Proctor T; Nikas IP; Awounvo S; Sepsa A; Georgoulias V; Ryu HS; Pateras IS; Kittas C
    Cancer Immunol Immunother; 2024 Feb; 73(3):46. PubMed ID: 38349444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.
    Okabe M; Toh U; Iwakuma N; Saku S; Akashi M; Kimitsuki Y; Seki N; Kawahara A; Ogo E; Itoh K; Akagi Y
    Cancer Sci; 2017 Jan; 108(1):81-90. PubMed ID: 27801993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
    Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
    BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
    Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
    Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effector memory cytotoxic CD3
    Sun X; Zhai J; Sun B; Parra ER; Jiang M; Ma W; Wang J; Kang AM; Kannan K; Pandurengan R; Zhang S; Solis LM; Haymaker CL; Raso MG; Mendoza Perez J; Sahin AA; Wistuba II; Yam C; Litton JK; Yang F
    Mod Pathol; 2022 May; 35(5):601-608. PubMed ID: 34839351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
    Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
    Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between high ratios of CD4/FOXP3 and CD8/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study.
    Tenggara JB; Rachman A; Prihartono J; Rachmadi L; Panigoro SS; Heriyanto DS; Sutandyo N; Nasution IR; Rahadiati FB; Steven R; Betsy R; Juanputra S; Sudoyo AW
    BMC Res Notes; 2024 Feb; 17(1):44. PubMed ID: 38308298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplexed immunofluorescence identifies high stromal CD68
    Wang J; Browne L; Slapetova I; Shang F; Lee K; Lynch J; Beretov J; Whan R; Graham PH; Millar EKA
    Sci Rep; 2021 Nov; 11(1):21608. PubMed ID: 34732817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological spatial analysis on the induction of PD-L1
    Suzuki K; Ohe R; Kabasawa T; Kitaoka T; Kawai M; Motoi F; Futakuchi M
    Breast Cancer; 2023 Nov; 30(6):1094-1104. PubMed ID: 37792212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma.
    Salisbury T; Abozina A; Zhang C; Mao E; Banyi N; Leo J; Ionescu D; Zhou C; Wang G
    Ann Diagn Pathol; 2022 Apr; 57():151901. PubMed ID: 35091156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma.
    Ottenhof SR; Djajadiningrat RS; Thygesen HH; Jakobs PJ; Jóźwiak K; Heeren AM; de Jong J; Sanders J; Horenblas S; Jordanova ES
    Front Immunol; 2018; 9():1253. PubMed ID: 29942303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
    Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
    Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes.
    Ni Y; Tsang JY; Shao Y; Poon IK; Tam F; Shea KH; Tse GM
    Oncologist; 2022 Apr; 27(4):e313-e327. PubMed ID: 35380716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.
    Sahin Ozkan H; Ugurlu MU; Yumuk PF; Kaya H
    Pathol Oncol Res; 2020 Oct; 26(4):2733-2745. PubMed ID: 32681436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer.
    Miller TJ; Anyaegbu CC; Lee-Pullen TF; Spalding LJ; Platell CF; McCoy MJ
    Cancer Sci; 2021 Mar; 112(3):1173-1183. PubMed ID: 33345422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
    Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and Clinical Significance of
    Shi S; Ma HY; Sang YZ; Ju YB; Liu XY; Zhang ZG
    Biomed Res Int; 2022; 2022():8118909. PubMed ID: 35845949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.
    Jung M; Rose M; Knuechel R; Loeffler C; Muti H; Kather JN; Gaisa NT;
    BMC Cancer; 2023 Feb; 23(1):113. PubMed ID: 36726072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.